Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 2432994-31-3
2. Kt-474
3. Kt474
4. N-[3-(difluoromethyl)-1-[trans-4-[[4-[[3-[1-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-3-methyl-2-oxo-1h-benzimidazol-4-yl]-2-propyn-1-yl]oxy]-1-piperidinyl]methyl]cyclohexyl]-1h-pyrazol-4-yl]-5-(1r,4r)-2-oxa-5-azabicyclo[2.2.1]hept-5-ylpyrazolo[1,5-a]pyrimidine-3-carboxamide
5. N-[3-(difluoromethyl)-1-[4-[[4-[3-[1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxobenzimidazol-4-yl]prop-2-ynoxy]piperidin-1-yl]methyl]cyclohexyl]pyrazol-4-yl]-5-[(1r,4r)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
6. 2sxr65p7e3
7. Schembl21998241
8. Schembl23807243
9. Schembl25986139
10. Gtpl12892
11. Kym-001
12. Glxc-26797
13. Glxc-27930
14. Ex-a8217
15. Kt-i-417
16. Sar444656
17. At41570
18. Kt-474?
19. Sar-444656
20. Compound A [wo2022174269a1]
21. Da-77150
22. Hy-145483
23. Cs-0374973
24. 5-((1r,4r)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)-n-(3-(difluoromethyl)-1-((1r,4r)-4-((4-((3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1h-benzo[d]imidazol-4-yl)prop-2-yn-1-yl)oxy)piperidin-1-yl)methyl)cyclohexyl)-1h-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
25. Pyrazolo(1,5-a)pyrimidine-3-carboxamide, N-(3-(difluoromethyl)-1-(trans-4-((4-((3-(1-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-3-methyl-2-oxo-1h-benzimidazol-4-yl)-2-propyn-1-yl)oxy)-1-piperidinyl)methyl)cyclohexyl)-1h-pyrazol-4-yl)-5-(1r,4r)-2-oxa-5-azabicyclo(2.2.1)hept-5-yl-
| Molecular Weight | 865.9 g/mol |
|---|---|
| Molecular Formula | C44H49F2N11O6 |
| XLogP3 | 2.5 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 13 |
| Rotatable Bond Count | 11 |
| Exact Mass | g/mol |
| Monoisotopic Mass | g/mol |
| Topological Polar Surface Area | 172 |
| Heavy Atom Count | 63 |
| Formal Charge | 0 |
| Complexity | 1790 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
Details:
Phathom intends to use the net proceeds from the offering to fund commercialization expenses and further clinical development of Voquezna (vonoprazan) for the treatment of Erosive GERD.
Lead Product(s): KT-474
Therapeutic Area: Dermatology Brand Name: SAR444656
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Morgan Stanley
Deal Size: $258.7 million Upfront Cash: Undisclosed
Deal Type: Public Offering August 21, 2024
Lead Product(s) : KT-474
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Morgan Stanley
Deal Size : $258.7 million
Deal Type : Public Offering
Kymera Therapeutics Announces Closing of Upsized $225 Million Public Offering
Details : Phathom intends to use the net proceeds from the offering to fund commercialization expenses and further clinical development of Voquezna (vonoprazan) for the treatment of Erosive GERD.
Brand Name : SAR444656
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 21, 2024
Details:
Kymera intends to use the net proceeds from the offering to continue advancing its pipeline, which includes SAR444656 (KT-474) being evaluated in the mid-stage for treating atopic dermatitis.
Lead Product(s): KT-474
Therapeutic Area: Dermatology Brand Name: SAR444656
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Morgan Stanley
Deal Size: $225.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering August 19, 2024
Lead Product(s) : KT-474
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Morgan Stanley
Deal Size : $225.0 million
Deal Type : Public Offering
Kymera Therapeutics Announces Pricing of $225 Million Public Offering
Details : Kymera intends to use the net proceeds from the offering to continue advancing its pipeline, which includes SAR444656 (KT-474) being evaluated in the mid-stage for treating atopic dermatitis.
Brand Name : SAR444656
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 19, 2024
Details:
SAR444656 (KT-474), a first-in-class IRAK4 degrader, being developed for the treatment of immune-inflammatory diseases, such as hidradenitis suppurativa, atopic dermatitis.
Lead Product(s): KT-474
Therapeutic Area: Dermatology Brand Name: SAR444656
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 08, 2024
Lead Product(s) : KT-474
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Kymera Expands KT-474 (SAR444656) HS and AD Phase 2 Studies After Safety Review
Details : SAR444656 (KT-474), a first-in-class IRAK4 degrader, being developed for the treatment of immune-inflammatory diseases, such as hidradenitis suppurativa, atopic dermatitis.
Brand Name : SAR444656
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 08, 2024
Details:
The net proceeds will advance the preclinical and clinical degrader programs, including SAR444656 (KT-474) for treating immune-inflammatory diseases like hidradenitis suppurativa & atopic dermatitis.
Lead Product(s): KT-474
Therapeutic Area: Dermatology Brand Name: SAR444656
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Morgan Stanley
Deal Size: $275.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 09, 2024
Lead Product(s) : KT-474
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Morgan Stanley
Deal Size : $275.0 million
Deal Type : Public Offering
Kymera Therapeutics Announces Closing Of Upsized $275 Million Public Offering
Details : The net proceeds will advance the preclinical and clinical degrader programs, including SAR444656 (KT-474) for treating immune-inflammatory diseases like hidradenitis suppurativa & atopic dermatitis.
Brand Name : SAR444656
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 09, 2024
Details:
Kymera will use proceeds to advance its degrader programs, including SAR444656, a first-in-class IRAK4 degrader, for treating hidradenitis suppurativa and atopic dermatitis.
Lead Product(s): KT-474
Therapeutic Area: Dermatology Brand Name: SAR444656
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Morgan Stanley
Deal Size: $275.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 05, 2024
Lead Product(s) : KT-474
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Morgan Stanley
Deal Size : $275.0 million
Deal Type : Public Offering
Kymera Therapeutics Announces Pricing of $275 Million Public Offering
Details : Kymera will use proceeds to advance its degrader programs, including SAR444656, a first-in-class IRAK4 degrader, for treating hidradenitis suppurativa and atopic dermatitis.
Brand Name : SAR444656
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 05, 2024
Details:
Kymera will use proceeds to advance its degrader programs, including SAR444656, a first-in-class IRAK4 degrader, for treating hidradenitis suppurativa and atopic dermatitis.
Lead Product(s): KT-474
Therapeutic Area: Dermatology Brand Name: SAR444656
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Morgan Stanley
Deal Size: $287.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 04, 2024
Lead Product(s) : KT-474
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Morgan Stanley
Deal Size : $287.5 million
Deal Type : Public Offering
Kymera Therapeutics Announces Proposed Public Offering
Details : Kymera will use proceeds to advance its degrader programs, including SAR444656, a first-in-class IRAK4 degrader, for treating hidradenitis suppurativa and atopic dermatitis.
Brand Name : SAR444656
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 04, 2024
Details:
Under the collaboration, Kymera is evaluating KT-474 (SAR444656), a first-in-class, investigational IRAK4 degrader, in the randomized Phase 2 clinical trial for Atopic Dermatitis.
Lead Product(s): KT-474
Therapeutic Area: Dermatology Brand Name: KT-474
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Sanofi
Deal Size: $2,150.0 million Upfront Cash: $150.0 million
Deal Type: Collaboration December 07, 2023
Lead Product(s) : KT-474
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Sanofi
Deal Size : $2,150.0 million
Deal Type : Collaboration
Details : Under the collaboration, Kymera is evaluating KT-474 (SAR444656), a first-in-class, investigational IRAK4 degrader, in the randomized Phase 2 clinical trial for Atopic Dermatitis.
Brand Name : KT-474
Molecule Type : Small molecule
Upfront Cash : $150.0 million
December 07, 2023
Details:
Under the collaboration, Kymera is evaluating KT-474 (SAR444656), a first-in-class, investigational IRAK4 degrader, in the randomized Phase 2 clinical trial in hidradenitis suppurativa.
Lead Product(s): KT-474
Therapeutic Area: Dermatology Brand Name: KT-474
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Sanofi
Deal Size: $2,150.0 million Upfront Cash: $150.0 million
Deal Type: Collaboration October 27, 2023
Lead Product(s) : KT-474
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Sanofi
Deal Size : $2,150.0 million
Deal Type : Collaboration
Details : Under the collaboration, Kymera is evaluating KT-474 (SAR444656), a first-in-class, investigational IRAK4 degrader, in the randomized Phase 2 clinical trial in hidradenitis suppurativa.
Brand Name : KT-474
Molecule Type : Small molecule
Upfront Cash : $150.0 million
October 27, 2023
Details:
In patients with HS and AD, KT-474 demonstrated plasma PK in Part C that was comparable to healthy volunteers in MAD3. Initial Phase 2 clinical trial of KT-474 will investigate its potential in HS and AD with the first study initiating in 2023.
Lead Product(s): KT-474
Therapeutic Area: Dermatology Brand Name: KT-474
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Sanofi
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2022
Lead Product(s) : KT-474
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Sanofi
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : In patients with HS and AD, KT-474 demonstrated plasma PK in Part C that was comparable to healthy volunteers in MAD3. Initial Phase 2 clinical trial of KT-474 will investigate its potential in HS and AD with the first study initiating in 2023.
Brand Name : KT-474
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 14, 2022
Details:
Data demonstrated that the clinical stage selective IRAK4 degrader KT-474 degrades IRAK4 and inhibits cytokine production in different immune and skin cell types.
Lead Product(s): KT-474
Therapeutic Area: Immunology Brand Name: KT-474
Study Phase: PreclinicalProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2022
Lead Product(s) : KT-474
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Data demonstrated that the clinical stage selective IRAK4 degrader KT-474 degrades IRAK4 and inhibits cytokine production in different immune and skin cell types.
Brand Name : KT-474
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 01, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
